Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 6/20 | 0.39 |
| ▸ | FAAH | O00519 | 6/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4601129 | 0.98 | ENPP2 (0.40) | ENPP2CA2FAAHCES2CES1 | |
| SCHEMBL4794021 | 0.79 | CA2 (0.45) | ENPP2CA2FAAHCES2CES1 | |
| SCHEMBL2251339 | 0.78 | ENPP2 (0.44) | ENPP2CA2FAAHCES2CES1 | |
| SCHEMBL5015091 | 0.77 | CA2 (0.48) | CA2FAAHCES2CES1TP53 | |
| SCHEMBL10616097 | 0.76 | ENPP2 (0.47) | ENPP2CA2FAAHCES2CES1 | |
| SCHEMBL2099691 | 0.74 | TDP1 (0.46) | CA2FAAHCES2CES1TP53 | |
| SCHEMBL4554474 | 0.74 | ENPP2 (0.46) | ENPP2CA2FAAHCES2CES1 | |
| SCHEMBL8634688 | 0.73 | FAAH (0.48) | ENPP2CA2FAAHCES2CES1 | |
| SCHEMBL2103322 | 0.73 | EPHX2 (0.47) | CA2FAAHCES2CES1 | |
| SCHEMBL2100773 | 0.73 | EPHX2 (0.47) | CA2FAAHCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117447505-A | Preparation method of beta-silicon-based amide-carboxylic acid medicine hybrid | 安阳师范学院 | 2024-01-26 | — | — | CN | claimed |
| EP-1912645-A2 | THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-04-23 | — | — | EP | claimed |
| WO-2007018314-A2 | THERAPEUTIC AGENT FOR DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | WO | claimed |
| US-4996360-A | Preparation of arylsulfonyl (alkyl) amides | ATOCHEM (FR) | 1991-02-26 | — | — | US | claimed |
| CN-117447505-A | Preparation method of beta-silicon-based amide-carboxylic acid medicine hybrid | 安阳师范学院 | 2024-01-26 | — | — | CN | disclosed |
| CN-117447505-A | Preparation method of beta-silicon-based amide-carboxylic acid medicine hybrid | 安阳师范学院 | 2024-01-26 | — | — | CN | disclosed |
| CN-115583961-A | Synthetic method of alpha-quaternary carbon beta-silicon-based amide | 安阳师范学院 | 2023-01-10 | — | — | CN | disclosed |
| CN-115583961-A | Synthetic method of alpha-quaternary carbon beta-silicon-based amide | 安阳师范学院 | 2023-01-10 | — | — | CN | disclosed |
| CN-113527267-B | C2 symmetric duplex nitrogen heterocyclic ring fluorocarbon surfactant and preparation of aqueous phase micelle thereof | 山东盛安贝新能源有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-113527264-B | Method for synthesizing nitrogen-containing heterocyclic fluorocarbon surfactant by adopting photoreaction-click reaction and preparation of aqueous phase micelle thereof | 山东盛安贝新能源有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-113527267-A | C2 symmetric duplex nitrogen heterocyclic ring fluorocarbon surfactant and preparation of aqueous phase micelle thereof | 山东盛安贝新能源有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-113527264-A | Method for synthesizing nitrogen-containing heterocyclic fluorocarbon surfactant by adopting photoreaction-click reaction and preparation of aqueous phase micelle thereof | 山东盛安贝新能源有限公司 | 2021-10-22 | — | — | CN | disclosed |
| EP-2118066-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | Takeda Pharmaceutical Company Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| WO-2008099794-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-21 | — | — | WO | disclosed |
| EP-1912645-A2 | THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
| WO-2007018314-A2 | THERAPEUTIC AGENT FOR DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | WO | disclosed |
| US-4996360-A | Preparation of arylsulfonyl (alkyl) amides | ATOCHEM (FR) | 1991-02-26 | — | — | US | disclosed |
| US-4996360-A | Preparation of arylsulfonyl (alkyl) amides | ATOCHEM (FR) | 1991-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | ENPP2 887/4885CA2 1474/4885FAAH 1354/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | ENPP2 1163/4885CA2 1306/4885FAAH 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.